RA Capital, a major investor and director, buys another $7.65M in Artiva Biotherapeutics stock
ARTV has more than doubled off its 52-week low of $1.47 on elevated volume (2.4× avg).
Summary
Major institutional investor RA Capital, with board representation, made an additional $7.65 million open market purchase of Artiva Biotherapeutics stock, signaling continued strong conviction.
Key Events · Ownership and Investor Activity · ARTV
-
Significant Insider Purchase
RA Capital Healthcare Fund LP, a 10% owner and director, purchased $7,650,148 worth of common stock in open market transactions between June 9 and June 11, 2026.
-
Continued Institutional Confidence
This purchase represents a substantial increase in holdings by a major institutional investor, following previous large buys by RA Capital and another 10% owner (GC Corp.) in May.
-
Transaction Details
The shares were acquired in three transactions at weighted average prices ranging from $6.91 to $7.91.
Analysis · ARTV · Life Sciences
RA Capital Healthcare Fund LP, a significant institutional investor with board representation, has continued to increase its stake in Artiva Biotherapeutics with a substantial open market purchase of $7.65 million. This follows a previous $100 million purchase by RA Capital in May and another $16.5 million purchase by GC Corp. in late May, indicating strong and sustained institutional confidence in the company.
At the time of this filing, ARTV was trading at $7.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $197.7M. The 52-week trading range was $1.47 to $14.53. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.